Post-fracture pharmacotherapy for women with osteoporotic fracture: analysis of a managed care population in the USA
暂无分享,去创建一个
[1] E. Losina,et al. The Potential Economic Benefits of Improved Postfracture Care: A Cost‐Effectiveness Analysis of a Fracture Liaison Service in the US Health‐Care System , 2014, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[2] S. Roux,et al. Priming Primary Care Physicians to Treat Osteoporosis After a Fragility Fracture: An Integrated Multidisciplinary Approach , 2013, The Journal of Rheumatology.
[3] P. Geusens,et al. Optimizing fracture prevention: the fracture liaison service, an observational study , 2013, Osteoporosis International.
[4] S. Tan,et al. Secondary prevention of osteoporotic fractures—an “OPTIMAL” model of care from Singapore , 2013, Osteoporosis International.
[5] Simon G A Brown. Treatment failure in osteoporosis. , 2012, Menopause international.
[6] S. Silverman,et al. Making the first fracture the last fracture: ASBMR task force report on secondary fracture prevention , 2012, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[7] L. Lix,et al. A population-based analysis of the post-fracture care gap 1996–2008: the situation is not improving , 2012, Osteoporosis International.
[8] L. Melton,et al. Lumbar spine bone mineral density in US adults: demographic patterns and relationship with femur neck skeletal status , 2012, Osteoporosis International.
[9] L. Ray,et al. Treatment for older men with fractures , 2012, Osteoporosis International.
[10] A. Roddam,et al. Persistence with osteoporosis medications among postmenopausal women in the UK General Practice Research Database , 2012, Menopause.
[11] A. LaCroix,et al. Predicting fractures in an international cohort using risk factor algorithms without BMD , 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[12] J. Abarca,et al. Analysis of the Comparative Effectiveness of 3 Oral Bisphosphonates in a Large Managed Care Organization: Adherence, Fracture Rates, and All-Cause Cost , 2011, Journal of managed care pharmacy : JMCP.
[13] R. Goeree,et al. The relative efficacy of nine osteoporosis medications for reducing the rate of fractures in post-menopausal women , 2011, BMC musculoskeletal disorders.
[14] C. Cooper,et al. Interpretation and use of FRAX in clinical practice , 2011, Osteoporosis International.
[15] D. Beaton,et al. Decision to take osteoporosis medication in patients who have had a fracture and are 'high' risk for future fracture: A qualitative study , 2011, BMC musculoskeletal disorders.
[16] S. Cummings,et al. Secular trends in the incidence of hip and other osteoporotic fractures , 2011, Osteoporosis International.
[17] B. Mcgowan,et al. Primary-care prescribing of anti-osteoporotic-type medications following hospitalisation for fractures , 2011, European Journal of Clinical Pharmacology.
[18] P. Cram,et al. Testing and treatment for osteoporosis following hip fracture in an integrated U.S. healthcare delivery system , 2011, Osteoporosis International.
[19] P. Lüthje,et al. Undertreatment of osteoporosis following hip fracture in the elderly. , 2009, Archives of gerontology and geriatrics.
[20] T. Weiss,et al. Predictors of falls among postmenopausal women: results from the National Osteoporosis Risk Assessment (NORA) , 2009, Osteoporosis International.
[21] P. Delmas,et al. Assessment of 10-year absolute fracture risk: a new paradigm with worldwide application , 2008, Osteoporosis International.
[22] C. Cooper,et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women , 2008, Osteoporosis International.
[23] Martha Timmer,et al. Systematic Review: Comparative Effectiveness of Treatments to Prevent Fractures in Men and Women with Low Bone Density or Osteoporosis , 2007, Annals of Internal Medicine.
[24] J. Eisman,et al. Residual Lifetime Risk of Fractures in Women and Men , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[25] A. Tosteson,et al. Incidence and Economic Burden of Osteoporosis‐Related Fractures in the United States, 2005–2025 , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[26] O. Johnell,et al. Multinational survey of osteoporotic fracture management , 2005, Osteoporosis International.
[27] D. Beaton,et al. Practice patterns in the diagnosis and treatment of osteoporosis after a fragility fracture: a systematic review , 2004, Osteoporosis International.
[28] S. Sen,et al. Undertreatment with anti-osteoporotic drugs after hospitalization for fracture , 2004, Osteoporosis International.
[29] R. Deyo,et al. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. , 1992, Journal of clinical epidemiology.
[30] D. Beaton,et al. Factors influencing the pharmacological management of osteoporosis after fragility fracture: results from the Ontario Osteoporosis Strategy’s fracture clinic screening program , 2013, Osteoporosis International.
[31] L. Lix,et al. Fracture risk assessment without bone density measurement in routine clinical practice , 2011, Osteoporosis International.
[32] M. Intorcia,et al. GRAND: the German retrospective cohort analysis on compliance and persistence and the associated risk of fractures in osteoporotic women treated with oral bisphosphonates , 2011, Osteoporosis International.
[33] J. Skedros,et al. Knowledge and opinions of orthopaedic surgeons concerning medical evaluation and treatment of patients with osteoporotic fracture. , 2006, The Journal of bone and joint surgery. American volume.